Myriad Genetics, Inc. (MYGN)

NASDAQ: MYGN · IEX Real-Time Price · USD
18.95
+0.05 (0.26%)
Jun 24, 2022 4:00 PM EDT - Market closed
0.26%
Market Cap 1.52B
Revenue (ttm) 682.40M
Net Income (ttm) -8.20M
Shares Out 80.34M
EPS (ttm) -0.11
PE Ratio n/a
Forward PE 13.39
Dividend n/a
Ex-Dividend Date n/a
Volume 763,638
Open 19.15
Previous Close 18.90
Day's Range 18.69 - 19.49
52-Week Range 16.02 - 36.95
Beta 1.57
Analysts Sell
Price Target 22.78 (+20.2%)
Earnings Date Aug 2, 2022

About MYGN

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancrea... [Read more...]

Industry Biotechnology
IPO Date Oct 5, 1995
CEO R. Bryan Riggsbee
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol MYGN
Full Company Profile

Financial Performance

In 2021, MYGN's revenue was $690.60 million, an increase of 8.14% compared to the previous year's $638.60 million. Losses were -$27.20 million, -86.37% less than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for MYGN stock is "Sell." The 12-month stock price forecast is 22.78, which is an increase of 20.21% from the latest price.

Price Target
$22.78
(20.21% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record ...

SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading...

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

New assay brings  validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development a...

Other symbols: ILMN

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

SALT LAKE CITY, June 09, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company's...

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Pr...

SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of ...

Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now

Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.

Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down

Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 40% and 3.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

SALT LAKE CITY, May 04, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be discussing the comp...

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offe...

SALT LAKE CITY, May 03, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the expansion of its strategic partnership wit...

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

SALT LAKE CITY, April 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first-quarter 2022 earnings conference call on...

2 Out of 3 Women With Depression or Anxiety Say They've Reached Their “Breaking Point” Yet More than Half Wait a Year...

Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns Six in 10 of the women...

Myriad Genetics (MYGN) Makes Progress in Precision Oncology

Myriad Genetics' (MYGN) Precise Oncology Solutions is a wide-ranging offering intended to help oncologists determine effective and personalized treatment plans for patients.

Reasons to Hold on to Myriad Genetics (MYGN) Stock For Now

Investors are optimistic about Myriad Genetics (MYGN), backed by growth in tumor profiling and GeneSight test volumes.

Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza

Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Test...

Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution Company launches Precise™ Tumor test, part of a com...

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Ca...

BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer BRACAnalysis CDx is now the only germline test...

Myriad Genetics Named to Fast Company's Annual List of World's Most Innovative Companies

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

SALT LAKE CITY, March 02, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be participating in ...

Myriad Genetics (MYGN) Reports Loss in Q4, Gross Margin Improves

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has drove Q4 sales despite a challenging business environment.

Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight®...

Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder Analysis shows combinatorial approach is m...

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

SALT LAKE CITY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its 2021 fourth-quarter earnings conference call on...

Myriad Genetics (MYGN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.